[Adsorbed influenza chemical vaccine in the immunization of schoolchildren]

Area of Science:

• Immunology
• Vaccinology
• Pediatric Infectious Diseases

Background:

• Influenza poses a significant health risk to children, necessitating effective vaccination strategies.
• Development of safe and potent influenza vaccines is crucial for public health.
• Assessing vaccine efficacy and safety in pediatric populations is essential.

Purpose of the Study:

• To evaluate the safety, reactogenicity, and antigenicity of an adsorbed chemical influenza vaccine in healthy children.
• To determine the optimal dosage of the influenza vaccine for different pediatric age groups (7-10 and 11-14 years).

Main Methods:

• Clinical trial involving healthy children aged 7-14 years.
• Administration of an adsorbed chemical influenza vaccine produced by the Mechnikov Research Institute for Vaccines and Sera.
• Assessment of vaccine safety, reactogenicity, and antigenic potency.

Main Results:

• The influenza vaccine demonstrated a favorable safety profile with low reactogenicity.
• The vaccine proved to be highly antigenically potent in the studied pediatric population.
• Optimal vaccine doses were successfully identified for children aged 7-10 years and 11-14 years.

Conclusions:

• The adsorbed chemical influenza vaccine is a safe and effective option for immunizing healthy children aged 7-14 years.
• The established optimal doses ensure potent immune responses in the target pediatric age groups.
• This research contributes to the ongoing efforts to control influenza through vaccination in children.